Biogen (BIIB)
(Delayed Data from NSDQ)
$197.59 USD
-0.62 (-0.31%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $197.58 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Company Summary
Based in Cambridge, MA, Biogen Inc. is one of the world’s leading biotechnology companies, which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer’s disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology.
Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy and Tysabri. Other approved/marketed products include Fumaderm (severe plaque psoriasis), Spinraza (spinal muscular ...
Company Summary
Based in Cambridge, MA, Biogen Inc. is one of the world’s leading biotechnology companies, which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer’s disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology.
Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy and Tysabri. Other approved/marketed products include Fumaderm (severe plaque psoriasis), Spinraza (spinal muscular atrophy (SMA), Qalsody for amyotrophic lateral sclerosis (ALS), Skyclarys for Friedreich's Ataxia and Leqembi (Alzheimer’s disease). Key MS drugs, Tecfidera and Tysabri, accounted for around 14% and 25.9% of the company’s 2023 product revenues, respectively. Spinraza accounted for 24% of Biogen’s total product revenues in 2023.
Biogen also generates significant royalties from partnership agreements with other pharmaceutical and biotechnology companies. It has collaborations with companies like Roche (Rituxan and Gazyva – cancer, Ocrevus – primary progressive MS and relapsing MS, Lunsumio - relapsed or refractory follicular lymphoma and Columvi – non-Hodgkin's lymphoma), Sage Therapeutics [Zurzuvae - postpartum depression (PPD)], Eisai (Leqembi – Alzheimer’s disease) and Ionis (Spinraza).
Biogen garnered total sales of $9.84 billion in 2023, down 3% year over year.
General Information
Biogen Inc
225 BINNEY STREET
CAMBRIDGE, MA 02142
Phone: 617-679-2000
Fax: 617-679-2617
Email: ir@biogen.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/13/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 3.81 |
Current Year EPS Consensus Estimate | 16.12 |
Estimated Long-Term EPS Growth Rate | 6.20 |
Exp Earnings Date | 11/13/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 198.21 |
52 Week High | 269.43 |
52 Week Low | 189.44 |
Beta | NA |
20 Day Moving Average | 768,896.81 |
Target Price Consensus | 270.81 |
4 Week | -3.54 |
12 Week | -11.19 |
YTD | -23.40 |
4 Week | -4.18 |
12 Week | -13.80 |
YTD | -35.16 |
Shares Outstanding (millions) | 145.66 |
Market Capitalization (millions) | 28,871.60 |
Short Ratio | NA |
Last Split Date | 1/18/2001 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 12.29 |
Trailing 12 Months | 12.19 |
PEG Ratio | 2.00 |
vs. Previous Year | 31.34% |
vs. Previous Quarter | 43.87% |
vs. Previous Year | 0.36% |
vs. Previous Quarter | 7.61% |
Price/Book | 1.82 |
Price/Cash Flow | 10.76 |
Price / Sales | 2.99 |
6/30/24 | 15.71 |
3/31/24 | 14.83 |
12/31/23 | 14.91 |
6/30/24 | 8.75 |
3/31/24 | 8.19 |
12/31/23 | 8.18 |
6/30/24 | 2.29 |
3/31/24 | 2.10 |
12/31/23 | 2.00 |
6/30/24 | 1.48 |
3/31/24 | 1.32 |
12/31/23 | 1.26 |
6/30/24 | 24.52 |
3/31/24 | 22.62 |
12/31/23 | 21.80 |
6/30/24 | 11.98 |
3/31/24 | 12.07 |
12/31/23 | 11.81 |
6/30/24 | 13.59 |
3/31/24 | 13.69 |
12/31/23 | 13.19 |
6/30/24 | 109.13 |
3/31/24 | 104.49 |
12/31/23 | 102.14 |
6/30/24 | 0.90 |
3/31/24 | 1.03 |
12/31/23 | 1.25 |
6/30/24 | 0.40 |
3/31/24 | 0.41 |
12/31/23 | 0.46 |
6/30/24 | 28.37 |
3/31/24 | 29.25 |
12/31/23 | 31.44 |